Key result
Genomic variations, including specific miRNAs and single nucleotide polymorphisms in AQP3 and RGS2 genes, are associated with the progression to cardiovascular disease and related risk factors following preeclampsia.
Why the study?
Women with prior preeclampsia face up to five times the risk of later-life CVD, but studies investigating their shared genomic variation over time are limited.
Does genomic variation associate with cardiovascular disease progression in women with a history of preeclampsia?
Systematic Review
Does genomic variation associate with cardiovascular disease progression in women with a history of preeclampsia?
There is highly heterogeneous preliminary evidence linking specific genomic variations to the progression of cardiovascular disease following preeclampsia, highlighting an urgent need for longitudinal studies.
Current evidence too heterogeneous for clinical use; leaves open whether genomics can refine post-preeclampsia CVD risk stratification.
Background Women with a history of preeclampsia (PE) have been shown to have up to five times the risk of developing later-life cardiovascular disease (CVD). While PE and CVD are known to share clinical and molecular characteristics, there are limited studies investigating their shared genomics (genetics, epigenetics or transcriptomics) variation over time. Therefore, we sought to systematically review the literature to identify longitudinal studies focused on the genomic progression to CVD following PE. Methods A literature search of primary sources through PubMed, Scopus, Web of Science and Embase via OVID was performed. Studies published from January 1 st , 1980, to February 02 nd , 2023, that investigated genomics in PE and CVD were eligible for inclusion. Studies that did not include CVD or related risk factors as outcome, were in non-human species or focused on pregnancy complications other than PE were excluded. Included studies were screened based on Cochrane systematic review guidelines in conjunction with the PRISMA 2020 checklist. Eligible articles were further assessed for quality using the Newcastle-Ottawa scale. Results A total of 8929 articles were screened with 14 studies subjected to quality assessment. Following further evaluation, six studies were included for final review. All six of these studies were heterogenous in regard to CVD/risk factor as outcome, gene mapping approach, and in different targeted genes. The only common variable across all six studies was use of a case-control study design. Conclusions Our results provide critical insight into the heterogeneous nature of genomic studies investigating CVD following PE and highlight the urgent need for longitudinal studies to further investigate the genetic variation underlying the progression to CVD following PE.
No takes yet. Share an insight, caveat, or question.
Krishnamurthy et al. (2023) conducted a systematic review in Cardiovascular disease progression following preeclampsia. Genomic variation (genetic, epigenetic, transcriptomic) vs. Normotensive pregnancy history or absence of specific genomic variation was evaluated on Progression to CVD endpoints or CVD risk factors. Genomic variations, including specific miRNAs and single nucleotide polymorphisms in AQP3 and RGS2 genes, are associated with the progression to cardiovascular disease and related risk factors following preeclampsia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: